Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide.

  • 2013-08-27
  • Alimentary pharmacology & therapeutics 38(8)
    • A P S Hungin
    • C Mulligan
    • B Pot
    • P Whorwell
    • L Agréus
    • P Fracasso
    • C Lionis
    • J Mendive
    • J-M Philippart de Foy
    • G Rubin
    • C Winchester
    • N de Wit

Study Design

Type
Systematic Review
Population
adults with lower gastrointestinal symptoms/problems, primarily IBS and AAD, from 37 RCTs
Methods
Systematic literature searching identified randomised, placebo-controlled trials in adults; evidence for each symptom/problem was graded and statements developed (consensus process; 10-member panel).
  • Highly Cited
  • Rigorous Journal

Background

Evidence suggests that the gut microbiota play an important role in gastrointestinal problems.

Aim

To give clinicians a practical reference guide on the role of specified probiotics in managing particular lower gastrointestinal symptoms/problems by means of a systematic review-based consensus.

Methods

Systematic literature searching identified randomised, placebo-controlled trials in adults; evidence for each symptom/problem was graded and statements developed (consensus process; 10-member panel). As results cannot be generalised between different probiotics, individual probiotics were identified for each statement.

Results

Thirty seven studies were included; mostly on irritable bowel syndrome [IBS; 19 studies; treatment responder rates: 18-80% (specific probiotics), 5-50% (placebo)] or antibiotic-associated diarrhoea (AAD; 10 studies). Statements with 100% agreement and 'high' evidence levels indicated that: (i) specific probiotics help reduce overall symptom burden and abdominal pain in some IBS patients; (ii) in patients receiving antibiotics/Helicobacter pylori eradication therapy, specified probiotics are helpful as adjuvants to prevent/reduce the duration/intensity of AAD; (iii) probiotics have favourable safety in patients in primary care. Items with 70-100% agreement and 'moderate' evidence were: (i) specific probiotics help relieve overall symptom burden in some patients with diarrhoea-predominant IBS, and reduce bloating/distension and improve bowel movement frequency/consistency in some IBS patients and (ii) with some probiotics, improved symptoms have led to improvement in quality of life.

Conclusions

Specified probiotics can provide benefit in IBS and antibiotic-associated diarrhoea; relatively few studies in other indications suggested benefits warranting further research. This study provides practical guidance on which probiotic to select for a specific problem.

Research Insights

    Back to top